MDS Alliance’s Post

View organization page for MDS Alliance, graphic

359 followers

The National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS). RYTELO™ (imetelstat) is now recommended as a Category 1 and 2A treatment for symptomatic anemia in patients with lower-risk #MDS. This update follows the recent FDA’s approval in June 2024 of #RYTELO (imetelstat) for adult patients with low- to intermediate-1 risk MDS who are transfusion-dependent and who have not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs). Read the full press release here: https://shorturl.at/ZG5bk #Research #BloodCancer

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics